HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Prognostic significance of Cyclin A in epidermoid anal cancer.

Abstract
Ultimately aiming at a more individualized therapeutic approach in epidermoid anal cancer, this study explored the prognostic and predictive impact of a set of tumour markers. From a population-based cohort of 276 patients with epidermoid anal cancer, treated according to prospective protocols, 215 pre-treatment biopsies were investigated using immunohistochemistry. The expression of p53, p21, Cyclin A and CD31 was measured semi-quantitatively. The expression rate was classified as high when immunostaining was seen in > 5% of the tumour cells for p53 and p21, > 20% in Cyclin A and, above median vessel count for CD31. Marker expression was correlated to survival and treatment response. A high Cyclin A expression correlated significantly with improved overall (77% vs 59%, p = 0.005) and tumour-specific (81% vs 64%, p = 0.009) survival at 5 years. Also, the locoregional failure rate was significantly lower in patients with a high Cyclin A expression (12% vs 24%, p < 0.05). In a multivariate Cox analysis Cyclin A was an independent prognostic factor. A low p21 expression correlated with a reduced rate of locoregional failure (14% vs 27%, p < 0.05) but no impact on survival was found. For p53 and CD31 no significant correlations were obtained. Cyclin A may be an indicator of radiosensitivity and a valuable prognostic marker in epidermoid anal cancer.
AuthorsPer J Nilsson, Claes Lenander, Carlos Rubio, Gert Auer, Olle Ljungqvist, Bengt Glimelius
JournalOncology reports (Oncol Rep) Vol. 16 Issue 3 Pg. 443-9 (Sep 2006) ISSN: 1021-335X [Print] Greece
PMID16865241 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Biomarkers, Tumor
  • CDKN1A protein, human
  • Cyclin A
  • Cyclin-Dependent Kinase Inhibitor p21
  • Platelet Endothelial Cell Adhesion Molecule-1
  • Tumor Suppressor Protein p53
Topics
  • Adult
  • Aged
  • Aged, 80 and over
  • Antineoplastic Combined Chemotherapy Protocols (therapeutic use)
  • Anus Neoplasms (metabolism, mortality, therapy)
  • Biomarkers, Tumor (metabolism)
  • Carcinoma, Squamous Cell (metabolism, mortality, therapy)
  • Cohort Studies
  • Cyclin A (metabolism)
  • Cyclin-Dependent Kinase Inhibitor p21 (metabolism)
  • Disease-Free Survival
  • Female
  • Humans
  • Male
  • Middle Aged
  • Platelet Endothelial Cell Adhesion Molecule-1 (metabolism)
  • Prospective Studies
  • Survival Rate
  • Treatment Outcome
  • Tumor Suppressor Protein p53 (metabolism)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: